{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:51:03Z","timestamp":1790661063500,"version":"4.1.0"},"reference-count":453,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1124\/pharmrev.121.000506","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T16:50:18Z","timestamp":1686847818000},"page":"1062-1118","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments"],"prefix":"10.1016","volume":"75","author":[{"given":"James E.","family":"Barrett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Shekarabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadet","family":"Inan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.121.000506_bib1","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/clpt.2011.188","article-title":"Cannabinoid-opioid interaction in chronic pain","volume":"90","author":"Abrams","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib2","first-page":"S2","article-title":"Updated studies on oxycodone, the active ingredient of the controlled-release formulation of oxycontin","volume":"66","author":"Aceto","year":"2002","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.117.014399","article-title":"Etiology and pharmacology of neuropathic pain","volume":"70","author":"Alles","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000506_bib4","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0269881116689257","article-title":"Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents","volume":"31","author":"Altarifi","year":"2017","journal-title":"J Psychopharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12927","article-title":"Role of orbitofrontal cortex in incubation of oxycodone craving in male rats","volume":"26","author":"Altshuler","year":"2021","journal-title":"Addict Biol"},{"key":"10.1124\/pharmrev.121.000506_bib6","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1124\/pharmrev.121.000506_bib7","doi-asserted-by":"crossref","first-page":"108614","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/00952998709001513","article-title":"Sex differences in addict careers. 4. Treatment","volume":"13","author":"Anglin","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1124\/pharmrev.121.000506_bib9","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/00952998709001500","article-title":"Sex differences in addict careers. 2. Becoming addicted","volume":"13","author":"Anglin","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1124\/pharmrev.121.000506_bib10","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1007\/s12035-021-02560-1","article-title":"Sex and estrous cycle differences in analgesia and brain oxycodone levels","volume":"58","author":"Arguelles","year":"2021","journal-title":"Mol Neurobiol"},{"key":"10.1124\/pharmrev.121.000506_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0304-3959(88)90198-4","article-title":"Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain","volume":"33","author":"Arn\u00e9r","year":"1988","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.brainres.2009.09.106","article-title":"Lateral hypothalamic orexin\/hypocretin neurons: a role in reward-seeking and addiction","volume":"1314","author":"Aston-Jones","year":"2010","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.121.000506_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0952-8180(96)00212-7","article-title":"Comparison of epidural morphine and oxycodone for pain after abdominal surgery","volume":"9","author":"Backlund","year":"1997","journal-title":"J Clin Anesth"},{"key":"10.1124\/pharmrev.121.000506_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3109\/00952990.2016.1167215","article-title":"Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users","volume":"42","author":"Backonja","year":"2016","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1124\/pharmrev.121.000506_bib15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.120.000124","article-title":"Monoclonal antibodies counteract opioid-induced behavioral and toxic effects in mice and rats","volume":"375","author":"Baehr","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib16","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41386-018-0197-3","article-title":"Vaccines to treat opioid use disorders and to reduce opioid overdoses","volume":"44","author":"Baehr","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/jat\/32.2.165","article-title":"A comparison of methadone, oxycodone, and hydrocodone related deaths in northeast Ohio","volume":"32","author":"Baker","year":"2008","journal-title":"J Anal Toxicol"},{"key":"10.1124\/pharmrev.121.000506_bib18","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.tips.2018.08.001","article-title":"Immunopharmacoherapies for treating opioid use disorder","volume":"39","author":"Banks","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000506_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bja\/aet127","article-title":"Sex differences in pain: a brief review of clinical and experimental findings","volume":"111","author":"Bartley","year":"2013","journal-title":"Br J Anaesth"},{"key":"10.1124\/pharmrev.121.000506_bib20","series-title":"Behavioral Pharmacology: The Current Status","first-page":"7","article-title":"Modification of the behavioral effects of drugs by environmental variables","author":"Barrett","year":"1985"},{"key":"10.1124\/pharmrev.121.000506_bib21","series-title":"Neurobiological Approaches to Brain Behavior Interactions","first-page":"161","article-title":"Historical influences affecting the behavioral actions of abused drugs","author":"Barrett","year":"1992"},{"key":"10.1124\/pharmrev.121.000506_bib22","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00429001","article-title":"Prior behavioral experience can reverse the effects of morphine","volume":"81","author":"Barrett","year":"1983","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib23","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.mp.4001504","article-title":"Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden","volume":"9","author":"Bart","year":"2004","journal-title":"Mol Psychiatry"},{"key":"10.1124\/pharmrev.121.000506_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/bph.15580","article-title":"Understanding and countering opioid-induced respiratory depression","volume":"180","author":"Bateman","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0022-3565(24)36827-2","article-title":"Sex differences in opioid antinociception","volume":"282","author":"Bartok","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1037\/1064-1297.12.3.163","article-title":"Discriminative stimulus, reinforcing, physical dependence, and antinociceptive effects of oxycodone in mice, rats, and rhesus monkeys","volume":"12","author":"Beardsley","year":"2004","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/009127007701700402","article-title":"Comparisons of the analgesic effects of oral and intramuscular oxymorphone and of intramuscular oxymorphone and morphine in patients with cancer","volume":"17","author":"Beaver","year":"1977","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S0022-3565(25)31396-0","article-title":"Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone","volume":"207","author":"Beaver","year":"1978","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib29","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-3565(25)31397-2","article-title":"Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine","volume":"207","author":"Beaver","year":"1978","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.yfrne.2007.07.003","article-title":"Sex differences in drug abuse","volume":"29","author":"Becker","year":"2008","journal-title":"Front Neuroendocrinol"},{"key":"10.1124\/pharmrev.121.000506_bib31","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/jnr.23963","article-title":"Sex differences, gender and addiction","volume":"95","author":"Becker","year":"2017","journal-title":"J Neurosci Res"},{"key":"10.1124\/pharmrev.121.000506_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/jpet.122.001217","article-title":"Zhx2 is a candidate gene underlying oxymorphone metabolite brain concentration associated with state-dependent oxycodone reward","volume":"382","author":"Beierle","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11306-016-1094-6","article-title":"Metabolomics enables precision medicine: a white paper, community perspective","volume":"12","author":"Beger","year":"2016","journal-title":"Metabolomics"},{"key":"10.1124\/pharmrev.121.000506_bib34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/J354v20n04_06","article-title":"High dose controlled-release oxycodone in hospice care","volume":"20","author":"Bercovitch","year":"2006","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1124\/pharmrev.121.000506_bib35","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1017\/S0140525X97221485","article-title":"Sex differences in pain","volume":"20","author":"Berkley","year":"1997","journal-title":"Behav Brain Sci"},{"key":"10.1124\/pharmrev.121.000506_bib36","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1126\/science.178.4067.1290","article-title":"Evidence for active immunity to morphine in mice","volume":"178","author":"Berkowitz","year":"1972","journal-title":"Science"},{"key":"10.1124\/pharmrev.121.000506_bib37","first-page":"406","article-title":"Experimental medicine. Experimental research on opium and its alkaloids","volume":"59","author":"Bernard","year":"1864","journal-title":"Compt Rend de Sc"},{"key":"10.1124\/pharmrev.121.000506_bib38","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1007\/s12035-018-1318-z","article-title":"Molecular adaptations in the rat dorsal striatum and hippocampus following abstinence-induced incubation of drug seeking after escalated oxycodone self-administration","volume":"56","author":"Blackwood","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.1124\/pharmrev.121.000506_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neuroscience.2019.07.030","article-title":"Escalated oxycodone self-administration causes differential striatal mRNA expression of FGFs and IEGs following abstinence-associated incubation of oxycodone craving","volume":"415","author":"Blackwood","year":"2019","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.121.000506_bib40","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3389\/fnins.2019.01392","article-title":"Escalated oxycodone self-administration and punishment: differential expression of opioid receptors and immediate early genes in the rat dorsal striatum and prefrontal cortex","volume":"13","author":"Blackwood","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib41","first-page":"127","article-title":"The addiction potential of oxycodone (Percodan)","volume":"99","author":"Bloomquist","year":"1963","journal-title":"Calif Med"},{"key":"10.1124\/pharmrev.121.000506_bib42","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/252708a0","article-title":"Changes in heroin self-administration by a rhesus monkey after morphine immunisation","volume":"252","author":"Bonese","year":"1974","journal-title":"Nature"},{"key":"10.1124\/pharmrev.121.000506_bib43","doi-asserted-by":"crossref","first-page":"7778","DOI":"10.1021\/acs.jmedchem.1c00611","article-title":"Novel dual-target m-opioid receptor and dopamine D3 receptor ligands as potential nonaddictive pharmacotherapeutics for main management","volume":"64","author":"Bonifazi","year":"2021","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.121.000506_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3959(95)00088-7","article-title":"Experimental pain stimulates respiration and attenuates morphine-induced respiratory depression: a controlled study in human volunteers","volume":"64","author":"Borgbjerg","year":"1996","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib45","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-like peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"key":"10.1124\/pharmrev.121.000506_bib46","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/ejn.13955","article-title":"Role of mu, but not delta or kappa, opioid receptors in context-induced reinstatement of oxycodone seeking","volume":"50","author":"Bossert","year":"2019","journal-title":"Eur J Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib47","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.biopsych.2020.02.014","article-title":"In a rat model of opioid maintenance, the G protein-biased mu opioid receptor agonist TRV130 decreases relapse to oxycodone seeking and taking and prevents oxycodone-induced brain hypoxia","volume":"88","author":"Bossert","year":"2020","journal-title":"Biol Psychiatry"},{"key":"10.1124\/pharmrev.121.000506_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bph.15679","article-title":"Sex differences in the effect of chronic delivery of the buprenorphine analogue BU08028 on heroin relapse and choice in a rat model of opioid maintenance","volume":"179","author":"Bossert","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/ALN.0b013e318164cf9e","article-title":"Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine","volume":"108","author":"Bostr\u00f6m","year":"2008","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.121.000506_bib50","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1124\/dmd.106.009746","article-title":"In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics\/pharmacodynamics","volume":"34","author":"Bostr\u00f6m","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.121.000506_bib51","doi-asserted-by":"crossref","first-page":"107859","DOI":"10.1016\/j.drugalcdep.2020.107859","article-title":"Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder","volume":"208","author":"Brandt","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib52","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1200\/JCO.1998.16.10.3222","article-title":"Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain","volume":"16","author":"Bruera","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1124\/pharmrev.121.000506_bib53","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/FBP.0000000000000690","article-title":"Oxycodone decreases anxiety-like behavior in the elevated plus-maze test in male and female rats","volume":"33","author":"Bruijnzeel","year":"2022","journal-title":"Behav Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib54","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.physbeh.2019.03.029","article-title":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review","volume":"206","author":"Brunchmann","year":"2019","journal-title":"Physiol Behav"},{"key":"10.1124\/pharmrev.121.000506_bib55","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/j.1532-2149.2012.00251.x","article-title":"Operant self-administration of a sigma ligand improves nociceptive and emotional manifestations of neuropathic pain","volume":"17","author":"Bura","year":"2013","journal-title":"Eur J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib56","doi-asserted-by":"crossref","first-page":"10830","DOI":"10.1073\/pnas.1300393110","article-title":"Discovery of positive allosteric modulators and silent allosteric modulators of the \u03bc-opioid receptor","volume":"110","author":"Burford","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.121.000506_bib57","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/bph.15592","article-title":"Insights into the mechanisms underlying opioid use disorder and potential treatment strategies","volume":"180","author":"Cao","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.drugalcdep.2015.12.026","article-title":"Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: a natural history study","volume":"160","author":"Carlson","year":"2016","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12994","article-title":"Adolescent oxycodone exposure inhibits withdrawal-induced expression of genes associated with the dopamine transmission","volume":"26","author":"Carpenter","year":"2021","journal-title":"Addict Biol"},{"key":"10.1124\/pharmrev.121.000506_bib60","doi-asserted-by":"crossref","first-page":"174111","DOI":"10.1016\/j.ejphar.2021.174111","article-title":"Validation and characterization of oxycodone physical dependence in C57BL\/6J mice","volume":"903","author":"Carper","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tips.2004.03.011","article-title":"Sex and estrogen influence drug abuse","volume":"25","author":"Carroll","year":"2004","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000506_bib62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/clpt.2013.235","article-title":"Progress in pharmacogenomics: bridging the gap from research to practice","volume":"95","author":"Cascorbi","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib63","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jpeds.2015.04.071","article-title":"Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: a national study","volume":"167","author":"Cerd\u00e1","year":"2015","journal-title":"J Pediatr"},{"key":"10.1124\/pharmrev.121.000506_bib64","unstructured":"Centers for Disease Control and Prevention (2021)."},{"key":"10.1124\/pharmrev.121.000506_bib65","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1021\/acs.biochem.0c00629","article-title":"Natural products for the treatment of pain: chemistry and pharmacology of salvinorin A, mitragynine, and collybolide","volume":"60","author":"Chakraborty","year":"2021","journal-title":"Biochemistry"},{"key":"10.1124\/pharmrev.121.000506_bib66","doi-asserted-by":"crossref","first-page":"173294","DOI":"10.1016\/j.pbb.2021.173294","article-title":"Sex differences in the rodent hippocampal opioid system following stress and oxycodone associated learning processes","volume":"212","author":"Chalangal","year":"2022","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib67","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1440-1681.2007.04821.x","article-title":"Sex differences in the pharmacokinetics, oxidative metabolism and oral bioavailability of oxycodone in the Sprague-Dawley rat","volume":"35","author":"Chan","year":"2008","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1124\/pharmrev.121.000506_bib68","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1365-2044.2010.06498.x","article-title":"A comparison of the respiratory effects of oxycodone versus morphine: a randomized, double-blind, placebo-controlled investigation","volume":"65","author":"Chang","year":"2010","journal-title":"Anaesthesia"},{"key":"10.1124\/pharmrev.121.000506_bib69","series-title":"Drug-Poisoning Deaths Involving Opioid Analgesics: United States, 1999\u20132011. NCHS Data Brief No. 166","author":"Chen","year":"2014"},{"key":"10.1124\/pharmrev.121.000506_bib70","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/0024-3205(91)90150-A","article-title":"Mu receptor binding of some commonly used opioids and their metabolites","volume":"48","author":"Chen","year":"1991","journal-title":"Life Sci"},{"issue":"2S","key":"10.1124\/pharmrev.121.000506_bib71","doi-asserted-by":"crossref","first-page":"SE33","DOI":"10.36076\/ppj.2017.sE52","article-title":"Oral oxycodone for acute postoperative pain: a review of clinical trials","volume":"20","author":"Cheung","year":"2017","journal-title":"Pain Physician"},{"key":"10.1124\/pharmrev.121.000506_bib72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0014-2999(00)00590-2","article-title":"Effect of nociptin \/orphanin FQ on the rewarding properties of morphine","volume":"404","author":"Ciccocioppo","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib73","series-title":"The Nocicepin\/Orphanin FQ Peptide Receptor. Handbook of Experimental Pharmacology, Vol. 254","first-page":"187","article-title":"NOP-related mechanisms in substance use disorders","author":"Ciccocioppo","year":"2020"},{"key":"10.1124\/pharmrev.121.000506_bib74","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0091-3057(02)01039-0","article-title":"Gender differences in the intravenous self-administration of mu opiate agonists","volume":"74","author":"Cicero","year":"2003","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib75","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/pds.1989","article-title":"Determinants of fentanyl and other potent \u00b5 opioid agonist misuse in opioid-dependent individuals","volume":"19","author":"Cicero","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1124\/pharmrev.121.000506_bib76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1056\/NEJMc1204141","article-title":"Effect of abuse-deterrent formulation of OxyContin","volume":"367","author":"Cicero","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000506_bib77","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1016\/j.pain.2013.07.025","article-title":"Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States","volume":"154","author":"Cicero","year":"2013","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib78","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jpain.2005.05.004","article-title":"Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002-2004","volume":"6","author":"Cicero","year":"2005","journal-title":"J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib79","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0022-3565(25)21187-9","article-title":"Gender-related differences in the antinociceptive properties of morphine","volume":"279","author":"Cicero","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib80","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0022-3565(24)36831-4","article-title":"Sex-related differences in morphine\u2019s antinociceptive activity: relationship to serum and brain morphine concentrations","volume":"282","author":"Cicero","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib81","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1016\/S0022-3565(25)24040-X","article-title":"The influence of pharmacogenetics on opioid analgesia: studies with codeine and oxycodone in the Sprague-Dawley\/Dark Agouti rat model","volume":"271","author":"Cleary","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib82","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00213-021-05814-x","article-title":"Evaluation of tradipitant, a selective NK1 antagonist, on response to oxycodone in humans","volume":"238","author":"Coe","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib83","first-page":"9","article-title":"Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: a meta-analysis","volume":"2","author":"Coller","year":"2009","journal-title":"Pharm Genomics Pers Med"},{"key":"10.1124\/pharmrev.121.000506_bib84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.pbb.2016.06.006","article-title":"Sex differences in responsiveness to the prescription opioid oxycodone in mice","volume":"148","author":"Collins","year":"2016","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib85","doi-asserted-by":"crossref","first-page":"107864","DOI":"10.1016\/j.neuropharm.2019.107864","article-title":"Murine model of OPRM1 A118G alters oxycodone self-administration and locomotor activation, but not conditioned place preference","volume":"167","author":"Collins","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib86","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0091-3057(99)00047-7","article-title":"Drug discrimination in neurobiology","volume":"64","author":"Colpaert","year":"1999","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib87","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0024-3205(82)90402-7","article-title":"Further evidence validating adjuvant arthritis as an experimental model of chronic pain in the rat","volume":"31","author":"Colpaert","year":"1982","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000506_bib88","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3959(00)00413-9","article-title":"Opiate self-administration as a measure of chronic pain in the rat","volume":"91","author":"Colpaert","year":"2001","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib89","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5055\/jom.2009.0022","article-title":"Relationship between rate of infusion and reinforcing strength of oxycodone in humans","volume":"5","author":"Comer","year":"2009","journal-title":"J Opioid Manag"},{"key":"10.1124\/pharmrev.121.000506_bib90","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/FBP.0b013e328363d1c4","article-title":"Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts","volume":"24","author":"Comer","year":"2013","journal-title":"Behav Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib91","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.drugalcdep.2009.12.018","article-title":"Abuse liability of oxycodone as a function of pain and drug use history","volume":"109","author":"Comer","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib92","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.npp.1301479","article-title":"Abuse liability of prescription opioids compared to heroin in morphine-maintained heroin abusers","volume":"33","author":"Comer","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib93","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0090-9556(25)08048-1","article-title":"Oxymorphone metabolism and urinary excretion in human, rat, guinea pig, rabbit, and dog","volume":"11","author":"Cone","year":"1983","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.121.000506_bib94","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s002130050298","article-title":"Modulating effects of a cold water stimulus on opioid effects in volunteers","volume":"131","author":"Conley","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib95","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s002130000453","article-title":"Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor","volume":"150","author":"Cook","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib96","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1124\/jpet.104.077792","article-title":"Nociceptive sensitivity and opioid antinociception and antihyperalgesia in Freund\u2019s adjuvant-induced arthritic male and female rats","volume":"313","author":"Cook","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib97","article-title":"Morphine for chronic neuropathic pain in adults","volume":"5","author":"Cooper","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000506_bib98","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41386-018-0011-2","article-title":"Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability","volume":"43","author":"Cooper","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib99","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/FBP.0b013e3283536d6f","article-title":"Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers","volume":"23","author":"Cooper","year":"2012","journal-title":"Behav Pharmacol"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000506_bib100","first-page":"S153","article-title":"75 years of opioid research: the exciting but vain quest for the Holy Grail","volume":"147","author":"Corbett","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib101","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00002508-200305000-00005","article-title":"Sex differences in opioid analgesia: \u201cfrom mouse to man.\u201d","volume":"19","author":"Craft","year":"2003","journal-title":"Clin J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib102","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1037\/a0012931","article-title":"Sex differences in analgesic, reinforcing, discriminative, and motoric effects of opioids","volume":"16","author":"Craft","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib103","first-page":"764","article-title":"Sex differences in discriminative stimulus effects of morphine in the rat","volume":"7","author":"Craft","year":"1996","journal-title":"Behav Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib104","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/clpt.2013.221","article-title":"Pharmacogenomics in psychiatry: from therapeutic drug monitoring to genomic medicine","volume":"95","author":"Crettol","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.copsyc.2018.07.014","article-title":"A review of opioid addiction genetics","volume":"27","author":"Crist","year":"2019","journal-title":"Curr Opin Psychol"},{"key":"10.1124\/pharmrev.121.000506_bib106","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/aas.13685","article-title":"Post-operative opioid-related adverse events with intravenous oxycodone compared to morphine: a randomized controlled trial","volume":"65","author":"Cuvillon","year":"2021","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1124\/pharmrev.121.000506_bib107","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejps.2016.04.027","article-title":"Systems pharmacology\u2014towards the modeling of network interactions","volume":"94","author":"Danhof","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"10.1124\/pharmrev.121.000506_bib108","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMsa1406143","article-title":"Trends in opioid analgesic abuse and mortality in the United States","volume":"372","author":"Dart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000506_bib109","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/32904","article-title":"Altered nociception, analgesia and aggression in mice lacking the receptor for substance P","volume":"392","author":"De Felipe","year":"1998","journal-title":"Nature"},{"key":"10.1124\/pharmrev.121.000506_bib110","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1111\/bph.12851","article-title":"Analgesic tolerance to morphine is regulated by PPAR\u03b3","volume":"171","author":"de Guglielmo","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib111","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fnbeh.2019.00292","article-title":"Dopamine D3 receptor antagonism reverses the escalation of oxycodone self-administration and decreases withdrawal-induced hyperalgesia and irritability-like behavior in oxycodone-dependent heterogeneous stock rats","volume":"13","author":"de Guglielmo","year":"2020","journal-title":"Front Behav Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib112","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/npp.2014.268","article-title":"PPAR\u03b3 activation attenuates opioid consumption and modulates mesolimbic dopamine transmission","volume":"40","author":"de Guglielmo","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib113","doi-asserted-by":"crossref","first-page":"115508","DOI":"10.1016\/j.jep.2022.115508","article-title":"Anti-inflammatory, antinociceptive effects and involvement of opioid receptors in the antinociceptive activity of Eugenia uniflora leaves obtained with water, ethanol, and propylene glycol mixture","volume":"296","author":"de Melo Candeia","year":"2022","journal-title":"J Ethnopharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib114","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1369-1600.2008.00129.x","article-title":"Impulsivity as a determinant and consequence of drug use: a review of underlying processes","volume":"14","author":"de Wit","year":"2009","journal-title":"Addict Biol"},{"key":"10.1124\/pharmrev.121.000506_bib115","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1054-3589(08)61114-X","article-title":"Pharmacological aspects of drug dependence","volume":"3","author":"Deneau","year":"1964","journal-title":"Adv Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib116","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3390\/pharmaceutics13091466","article-title":"Contribution of CYP2D6 functional activity to oxycodone efficacy in pain management: genetic polymorphisms, phenoconversion, and tissue-selective metabolism","volume":"13","author":"Deodhar","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1124\/pharmrev.121.000506_bib117","article-title":"Fentanyl for neuropathic pain in adults","volume":"10","author":"Derry","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000506_bib118","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0196-9781(00)00250-3","article-title":"Nociceptin differentially affects morphine-induced dopamine release from the nucleus accumbens and nucleus caudate in rats","volume":"21","author":"Di Giannuario","year":"2000","journal-title":"Peptides"},{"key":"10.1124\/pharmrev.121.000506_bib119","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0304-3940(99)00579-0","article-title":"Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats","volume":"272","author":"Di Giannuario","year":"1999","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.121.000506_bib120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0304-3959(82)90008-2","article-title":"Intracerebroventricular self-injection of morphine in response to pain in the rat","volume":"13","author":"Dib","year":"1982","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib121","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/bph.15791","article-title":"Increased heroin intake and relapse vulnerability in intermittent relative to continuous self-administration: sex differences in rats","volume":"180","author":"D\u2019Ottavio","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib122","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behav Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib123","first-page":"569","article-title":"Synthetic substances with morphine-like effect: clinical experience: potency, side-effects, addiction liability","volume":"17","author":"Eddy","year":"1957","journal-title":"Bull World Health Organ"},{"key":"10.1124\/pharmrev.121.000506_bib124","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/00002508-200307000-00003","article-title":"Differential relationships between anxiety and treatment-associated pain reduction among male and female chronic pain patients","volume":"19","author":"Edwards","year":"2003","journal-title":"Clin J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib125","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0006-8993(86)90691-8","article-title":"Behavioural effects of tachykinins and related peptides","volume":"381","author":"Elliott","year":"1986","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.121.000506_bib126","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD012509","article-title":"High-dose opioids for chronic non-cancer pain: an overview of Cochrane Reviews","volume":"10","author":"Els","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000506_bib127","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2016.07.006","article-title":"Oxycodone physical dependence and its oral self-administration in C57BL\/6J mice","volume":"789","author":"Enga","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib128","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1208\/s12248-015-9776-y","article-title":"Computational advances for the development of allosteric modulators and bitopic ligands in G-protein-coupled receptors","volume":"17","author":"Feng","year":"2015","journal-title":"AAPS J"},{"key":"10.1124\/pharmrev.121.000506_bib129","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00003643-200219261-00004","article-title":"Sex differences in analgesic responses: evidence from experimental pain models","volume":"26","author":"Fillingim","year":"2002","journal-title":"Eur J Anaesthesiol Suppl"},{"key":"10.1124\/pharmrev.121.000506_bib130","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ejpain.2004.01.007","article-title":"Sex differences in opioid analgesia: clinical and experimental findings","volume":"8","author":"Fillingim","year":"2004","journal-title":"Eur J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib131","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/15287390600870924","article-title":"Oxycodone abuse in Texas, 1998-2004","volume":"70","author":"Forrester","year":"2007","journal-title":"J Toxicol Environ Health A"},{"key":"10.1124\/pharmrev.121.000506_bib132","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/1096-8628(20010108)105:1<114::AID-AJMG1074>3.0.CO;2-L","article-title":"Nonreplication of association between \u03bc-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence","volume":"105","author":"Franke","year":"2001","journal-title":"Am J Med Genet"},{"key":"10.1124\/pharmrev.121.000506_bib133","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0022-3565(25)26118-3","article-title":"Methods for evaluating addiction liability. (A) \u201cAttitude\u201d of opiate addicts toward opiate-like drugs. (B) a short-term \u201cdirect\u201d addiction test","volume":"133","author":"Fraser","year":"1961","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib134","doi-asserted-by":"crossref","first-page":"eadd8687","DOI":"10.1126\/sciadv.add8687","article-title":"Role of ventral subiculum neuronal ensembles in incubation of oxycodone craving after electric barrier-induced voluntary abstinence","volume":"9","author":"Fredriksson","year":"2023","journal-title":"Sci Adv"},{"key":"10.1124\/pharmrev.121.000506_bib135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bph.12663","article-title":"Heteromers of \u03bc-\u03b4 opioid receptors: new pharmacology and novel therapeutic possibilities","volume":"172","author":"Fujita","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib136","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0014-2999(89)90132-5","article-title":"Effects of a selective kappa-opioid agonist, U-50,488H, on morphine dependence in rats","volume":"170","author":"Fukagawa","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib137","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12822","article-title":"Sex differences in oral oxycodone self-administration and stress-primed reinstatement in rats","volume":"25","author":"Fulenwider","year":"2020","journal-title":"Addict Biol"},{"key":"10.1124\/pharmrev.121.000506_bib138","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/bph.15792","article-title":"Central metabolism as a potential origin of sex differences in morphine antinociception but not induction of antinociceptive tolerance in mice","volume":"180","author":"Gabel","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib139","doi-asserted-by":"crossref","first-page":"8271","DOI":"10.1523\/JNEUROSCI.23-23-08271.2003","article-title":"Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse","volume":"23","author":"Gadd","year":"2003","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1080\/07853890.2022.2067350","article-title":"Opioid overdose decedent characteristics during COVID-19","volume":"54","author":"Garcia","year":"2022","journal-title":"Ann Med"},{"key":"10.1124\/pharmrev.121.000506_bib141","article-title":"Oxycodone for neuropathic pain in adults","volume":"7","author":"Gaskell","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000506_bib142","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/npp.2017.4","article-title":"RGS9-2 modulates responses to oxycodone in pain-free and chronic pain states","volume":"42","author":"Gaspari","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib143","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1038\/npp.2014.45","article-title":"Nucleus accumbens-specific interventions in RGS9-2 activity modulate responses to morphine","volume":"39","author":"Gaspari","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib144","doi-asserted-by":"crossref","first-page":"109828","DOI":"10.1016\/j.drugalcdep.2023.109828","article-title":"The centrality of craving in network analysis of five substance use disorders","volume":"245","author":"Gauld","year":"2023","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib145","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1523\/JNEUROSCI.23-08-03106.2003","article-title":"Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal","volume":"23","author":"Georgescu","year":"2003","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib146","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/FBP.0000000000000126","article-title":"\u03bc-Opioid and N-methyl-D-aspartate receptors in the amygdala contribute to minocycline-induced potentiation of morphine analgesia in rats","volume":"26","author":"Ghazvini","year":"2015","journal-title":"Behav Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib147","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00002508-199006000-00012","article-title":"Patient-controlled analgesia in postoperative pain: the relation of psychological factors to pain and analgesic use","volume":"6","author":"Gil","year":"1990","journal-title":"Clin J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib148","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/01.WNL.0000057720.36503.2C","article-title":"Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial","volume":"60","author":"Gimbel","year":"2003","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.121.000506_bib149","first-page":"1","article-title":"Drug discrimination: applications to drug abuse research","volume":"116","author":"Glennon","year":"1991","journal-title":"Natl Inst Drug Abuse Res Monogr Ser"},{"key":"10.1124\/pharmrev.121.000506_bib150","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/med.2610030305","article-title":"Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents","volume":"3","author":"Glennon","year":"1983","journal-title":"Med Res Rev"},{"key":"10.1124\/pharmrev.121.000506_bib151","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.6682244","article-title":"Drug history modifies the behavioral effects of pentobarbital","volume":"220","author":"Glowa","year":"1983","journal-title":"Science"},{"key":"10.1124\/pharmrev.121.000506_bib152","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/0024-3205(86)90287-0","article-title":"Kappa receptor mediated opioid dependence in rhesus monkeys","volume":"39","author":"Gmerek","year":"1986","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000506_bib153","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.brainres.2017.08.017","article-title":"Reversal of oxycodone and hydrocodone tolerance by diazepam","volume":"1674","author":"Gonek","year":"2017","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.121.000506_bib154","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.phrs.2011.06.022","article-title":"Oxycodone dose-dependently imparts conditioned reinforcing properties to discrete sensory stimuli in rats","volume":"64","author":"Grella","year":"2011","journal-title":"Pharmacol Res"},{"key":"10.1124\/pharmrev.121.000506_bib155","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2022.1035350","article-title":"Ranking the contribution of behavioral measures comprising oxycodone self-administration to reinstatement of drug-seeking in male and female rats","volume":"16","author":"Guha","year":"2022","journal-title":"Front Behav Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib156","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12871-018-0583-8","article-title":"Comparison of analgesic effect of oxycodone and morphine on patients with moderate and advanced cancer pain: a meta-analysis","volume":"18","author":"Guo","year":"2018","journal-title":"BMC Anesthesiol"},{"key":"10.1124\/pharmrev.121.000506_bib157","series-title":"Drugs of Choice 1976\u20131977","first-page":"213","article-title":"Analgesics","author":"Halpern","year":"1976"},{"key":"10.1124\/pharmrev.121.000506_bib158","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1016\/j.vaccine.2022.03.053","article-title":"Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder","volume":"40","author":"Hamid","year":"2022","journal-title":"Vaccine"},{"issue":"6S","key":"10.1124\/pharmrev.121.000506_bib159","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.arth.2022.02.037","article-title":"Prospective randomized study using pharmacogenetics to customize postoperative pain medication following hip and knee arthroplasty","volume":"37","author":"Hamilton","year":"2022","journal-title":"J Arthroplasty"},{"key":"10.1124\/pharmrev.121.000506_bib160","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature04071","article-title":"A role for lateral hypothalamic orexin neurons in reward seeking","volume":"437","author":"Harris","year":"2005","journal-title":"Nature"},{"key":"10.1124\/pharmrev.121.000506_bib161","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00213-012-2738-5","article-title":"The effect of morphine dependence on impulsive choice in rats","volume":"223","author":"Harvey-Lewis","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib162","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1002\/jps.20893","article-title":"Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel\u2019s tissue distribution in Sprague Dawley rats","volume":"96","author":"Hassan","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1124\/pharmrev.121.000506_bib163","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1749-6632.2009.05149.x","article-title":"Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders","volume":"1187","author":"Heidbreder","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/pharmrev.121.000506_bib164","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0304-3959(97)00072-9","article-title":"Controlled-release oxycodone and morphine in cancer related pain","volume":"73","author":"Heiskanen","year":"1997","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib165","doi-asserted-by":"crossref","first-page":"107961","DOI":"10.1016\/j.pharmthera.2021.107961","article-title":"Experimental considerations for the assessment of in vivo and in vitro opioid pharmacology","volume":"230","author":"Hill","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib166","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1111\/bph.14219","article-title":"Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition","volume":"175","author":"Hill","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib167","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.134.3483.943","article-title":"Progressive ratio as a measure of reward strength","volume":"134","author":"Hodos","year":"1961","journal-title":"Science"},{"key":"10.1124\/pharmrev.121.000506_bib168","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1124\/pharmrev.121.000506_bib169","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pbb.2005.12.013","article-title":"Characterization of the antinociceptive effect of oxycodone in male and female rats","volume":"83","author":"Holtman","year":"2006","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib170","first-page":"178","article-title":"Immunotherapies for the treatment of drug addiction","volume":"10","author":"Hossain","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1124\/pharmrev.121.000506_bib171","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3109\/00952998709001512","article-title":"Sex differences in addict careers. 3. Addiction","volume":"13","author":"Hser","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1124\/pharmrev.121.000506_bib172","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/00952998709001499","article-title":"Sex differences in addict careers. 1. Initiation of use","volume":"13","author":"Hser","year":"1987","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1124\/pharmrev.121.000506_bib173","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003348.pub2","article-title":"Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain","volume":"4","author":"Hudcova","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000506_bib174","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/FBP.0000000000000543","article-title":"Effects of oxycodone on sensitivity to reinforcement magnitude: Implications for effects of opioids on impulsive and risky choice","volume":"31","author":"Hunt","year":"2020","journal-title":"Behav Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib175","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbi.2008.09.012","article-title":"Reduction in opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast)","volume":"23","author":"Hutchinson","year":"2009","journal-title":"Brain Behav Immun"},{"key":"10.1124\/pharmrev.121.000506_bib176","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.bbi.2008.07.008","article-title":"Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia","volume":"22","author":"Hutchinson","year":"2008","journal-title":"Brain Behav Immun"},{"key":"10.1124\/pharmrev.121.000506_bib177","series-title":"International Classification of Diseases 11th Revision","year":"2018"},{"key":"10.1124\/pharmrev.121.000506_bib178","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuroscience.2018.11.042","article-title":"Oxycodone exposure: a magnetic resonance imaging study in response to acute and chronic oxycodone treatment in rats","volume":"398","author":"Iriah","year":"2019","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.121.000506_bib179","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1248\/bpb1978.5.521","article-title":"Determination of oxycodone metabolites in urines and feces of several mammalian species","volume":"5","author":"Ishida","year":"1982","journal-title":"J Pharmacobiodyn"},{"key":"10.1124\/pharmrev.121.000506_bib180","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/gbb.12393","article-title":"Variability in prescription opioid intake and reinforcement amongst 129 substrains","volume":"16","author":"Jimenez","year":"2017","journal-title":"Genes Brain Behav"},{"key":"10.1124\/pharmrev.121.000506_bib1801","article-title":"Trends in the distribution of selected opioids by state, U.S., 1999\u20132001","author":"Jones","year":"2013","journal-title":"National Meet Safe States Alliance"},{"key":"10.1124\/pharmrev.121.000506_bib181","doi-asserted-by":"crossref","first-page":"172778","DOI":"10.1016\/j.pbb.2019.172778","article-title":"Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone","volume":"186","author":"Jones","year":"2019","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib182","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.physbeh.2015.10.006","article-title":"The effects of pioglitazone, a PPAR\u03b3 receptor agonist, on the abuse liability of oxycodone among nondependent opioid users","volume":"159","author":"Jones","year":"2016","journal-title":"Physiol Behav"},{"key":"10.1124\/pharmrev.121.000506_bib183","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/npp.2010.172","article-title":"The subjective, reinforcing, and analgesic effects of oxycodone in patients with chronic, non-malignant pain who are maintained on sublingual buprenorphine\/naloxone","volume":"36","author":"Jones","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib184","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0009-9236(96)90024-7","article-title":"Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone","volume":"59","author":"Kaiko","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib185","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3389\/fpsyt.2019.00592","article-title":"Craving in opioid use disorder: from neurobiology to clinical practice","volume":"10","author":"Kakko","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1124\/pharmrev.121.000506_bib186","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1073\/pnas.1915143117","article-title":"Nociceptin attenuates the escalation of oxycodone self-administration by normalizing CeA-GABA transmission in highly addicted rats","volume":"117","author":"Kallupi","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Suppl 5","key":"10.1124\/pharmrev.121.000506_bib187","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jpainsymman.2005.01.010","article-title":"Oxycodone","volume":"29","author":"Kalso","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"10.1124\/pharmrev.121.000506_bib188","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pain.2007.09.027","article-title":"How different is oxycodone from morphine?","volume":"132","author":"Kalso","year":"2007","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib189","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1399-6576.1991.tb03364.x","article-title":"Intravenous morphine and oxycodone for pain after abdominal surgery","volume":"35","author":"Kalso","year":"1991","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1124\/pharmrev.121.000506_bib190","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/clpt.1990.85","article-title":"Morphine and oxycodone hydrochloride in the management of cancer pain","volume":"47","author":"Kalso","year":"1990","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib191","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0006-8993(92)90655-S","article-title":"Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by m-opioid agonists, but not by \u03b4-and \u03ba\u2212opioid agonists","volume":"571","author":"Kamei","year":"1992","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.121.000506_bib192","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1254\/jphs.14133FP","article-title":"The contribution of Gi\/o protein to opioid antinociception in an oxaliplatin-induced neuropathy rat model","volume":"126","author":"Kanbara","year":"2014","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000506_bib193","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.pain.2014.06.010","article-title":"Operant nociception in nonhuman primates","volume":"155","author":"Kangas","year":"2014","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib194","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/15360288.2015.1037521","article-title":"The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response","volume":"29","author":"Kanouse","year":"2015","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"10.1124\/pharmrev.121.000506_bib195","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/AJP.0b013e318167a087","article-title":"Internet-based survey of nonmedical prescription opioid use in the United States","volume":"24","author":"Katz","year":"2008","journal-title":"Clin J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib196","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/pr.118.016790","article-title":"Biased receptor signaling in drug discovery","volume":"71","author":"Kenakin","year":"2019","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000506_bib197","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00000542-200008000-00034","article-title":"Gender differences in opioid-mediated analgesia: animal and human studies","volume":"93","author":"Kest","year":"2000","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.121.000506_bib198","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/ALN.0000000000004065","article-title":"Opioids and public health: the prescription opioid ecosystem and need for improved management","volume":"136","author":"Kharasch","year":"2022","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.121.000506_bib199","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10571-020-01013-y","article-title":"Oxycodone in the opioid epidemic: high \u201cliking,\u201d \u201cwanting,\u201d and abuse liability","volume":"41","author":"Kibaly","year":"2021","journal-title":"Cell Mol Neurobiol"},{"key":"10.1124\/pharmrev.121.000506_bib200","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00213-003-1697-2","article-title":"Effects of morphine and naltrexone on impulsive decision making in rats","volume":"173","author":"Kieres","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib201","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0091-3057(78)90295-2","article-title":"Effects of passive immunization against morphine on heroin self-administration","volume":"9","author":"Killian","year":"1978","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib202","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00213-020-05479-y","article-title":"Oxycodone self-administration and withdrawal behaviors in male and female Wistar rats","volume":"237","author":"Kimbrough","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib203","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1021\/acschembio.6b00977","article-title":"An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life","volume":"12","author":"Kimishima","year":"2017","journal-title":"ACS Chem Biol"},{"key":"10.1124\/pharmrev.121.000506_bib204","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","article-title":"Updated clinical pharmacokinetics and pharmacodynamics of oxycodone","volume":"58","author":"Kinnunen","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pharmrev.121.000506_bib205","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neuropharm.2019.02.008","article-title":"Respiratory depression and brain hypoxia induced by opioid drugs: morphine, oxycodone, heroin, and fentanyl","volume":"151","author":"Kiyatkin","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib206","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib207","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev-publhealth-031914-122957","article-title":"The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction","volume":"36","author":"Kolodny","year":"2015","journal-title":"Annu Rev Public Health"},{"issue":"3, Suppl","key":"10.1124\/pharmrev.121.000506_bib208","doi-asserted-by":"crossref","first-page":"ES39","DOI":"10.36076\/ppj.2012\/15\/ES39","article-title":"A systematic review of randomized trials on the effectiveness of opioids for cancer pain","volume":"15","author":"Koyyalagunta","year":"2012","journal-title":"Pain Physician"},{"key":"10.1124\/pharmrev.121.000506_bib209","doi-asserted-by":"crossref","first-page":"7634","DOI":"10.1021\/acs.jmedchem.6b00860","article-title":"Highly selective dopamine D3 receptor (D3R) antagonists and partial agonists based on eticlopride and the D3R crystal structure: new leads for opioid dependence treatment","volume":"59","author":"Kumar","year":"2016","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.121.000506_bib210","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bph.12696","article-title":"In vivo profiling of seven common opioids for antinociception, constipation and respiratory depression: no two opioids have the same profile","volume":"172","author":"Kuo","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib211","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites","volume":"79","author":"Lalovic","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib212","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tips.2012.10.003","article-title":"Bridging the gap: bitopic ligands of G-protein-coupled receptors","volume":"34","author":"Lane","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000506_bib213","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/jama.1955.02950290026009","article-title":"Drug-induced mood changes in man. I. Observations on healthy subjects, chronically ill patients, and postaddicts","volume":"157","author":"Lasagna","year":"1955","journal-title":"J Am Med Assoc"},{"key":"10.1124\/pharmrev.121.000506_bib214","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bph.15765","article-title":"Metabolic interactions of benzodiazepines with oxycodone ex vivo and toxicity depending on usage patterns in an animal model","volume":"180","author":"Lawson","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib215","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1046\/j.1365-2044.1999.00946.x","article-title":"Time course of changes in breathing pattern in morphine- and oxycodone-induced respiratory depression","volume":"54","author":"Leino","year":"1999","journal-title":"Anaesthesia"},{"key":"10.1124\/pharmrev.121.000506_bib216","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S1877-8860(09)70005-9","article-title":"Pharmacology of oxycodone: does it explain why oxycodone has become a bestselling strong opioid","volume":"1","author":"Lemberg","year":"2009","journal-title":"Scand J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib217","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/00000542-200610000-00027","article-title":"Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats","volume":"105","author":"Lemberg","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.121.000506_bib218","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1213\/01.ane.0000205751.88422.41","article-title":"Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat","volume":"102","author":"Lemberg","year":"2006","journal-title":"Anesth Analg"},{"key":"10.1124\/pharmrev.121.000506_bib219","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/01.anes.0000265177.13490.53","article-title":"Oxycodone\u2019s mechanism of action and potency differences after spinal and systemic routes of administration","volume":"106","author":"Lemberg","year":"2007","journal-title":"Anesthesiol"},{"key":"10.1124\/pharmrev.121.000506_bib220","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1213\/ane.0b013e3181605a15","article-title":"Pharmacological characterization of noroxymorphone as a new opioid for spinal analgesia","volume":"106","author":"Lemberg","year":"2008","journal-title":"Anesth Analg"},{"key":"10.1124\/pharmrev.121.000506_bib221","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/FBP.0000000000000542","article-title":"Effects of oxycodone and diazepam alone and in combination on operant nociception","volume":"31","author":"Leonard","year":"2020","journal-title":"Behav Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib222","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/0024-3205(94)00849-3","article-title":"The antinociceptive potencies of oxycodone, noroxycodone and morphine after intracerebroventricular administration to rats","volume":"54","author":"Leow","year":"1994","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000506_bib223","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.pbb.2005.08.008","article-title":"Ultra-low-dose naltrexone reduces the rewarding potency of oxycodone and relapse vulnerability in rats","volume":"82","author":"Leri","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib224","article-title":"ZHX2 in health and disease","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1124\/pharmrev.121.000506_bib225","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.bja.2017.11.081","article-title":"Ketamine and norketamine attenuate oxycodone tolerance markedly less than that of morphine: from behaviour to drug availability","volume":"120","author":"Lilius","year":"2018","journal-title":"Br J Anaesth"},{"key":"10.1124\/pharmrev.121.000506_bib226","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/pme.12380","article-title":"Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness","volume":"15","author":"Linares","year":"2014","journal-title":"Pain Med"},{"key":"10.1124\/pharmrev.121.000506_bib227","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1038\/clpt.2008.64","article-title":"Plasma concentrations of oral oxycodone are greatly increased in the elderly","volume":"84","author":"Liukas","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib228","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.drugalcdep.2011.11.018","article-title":"Effects of cold pressor pain on the abuse liability of intranasal oxycodone in male and female prescription opioid abusers","volume":"123","author":"Lofwall","year":"2012","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib229","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s40140-020-00420-7","article-title":"Insights into the neurobiology of craving in opioid use disorder","volume":"10","author":"Lueptow","year":"2020","journal-title":"Curr Anesthesiol Rep"},{"key":"10.1124\/pharmrev.121.000506_bib230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s002130050979","article-title":"Sex differences in the acquisition of intravenously self-administered cocaine and heroin in rats","volume":"144","author":"Lynch","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib231","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-002-1183-2","article-title":"Biological basis of sex differences in drug abuse: preclinical and clinical studies","volume":"164","author":"Lynch","year":"2002","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib232","doi-asserted-by":"crossref","DOI":"10.1128\/msystems.00336-22","article-title":"Long-term effects of developmental exposure to oxycodone on gut microiota and relationship to adult behaviors and metabolism","volume":"7","author":"Lyu","year":"2022","journal-title":"mSystems"},{"key":"10.1124\/pharmrev.121.000506_bib233","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0885-3924(96)00050-4","article-title":"Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone","volume":"12","author":"Maddocks","year":"1996","journal-title":"J Pain Symptom Manage"},{"key":"10.1124\/pharmrev.121.000506_bib234","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.vascn.2012.08.168","article-title":"Impulsivity and drugs of abuse: a juice-reinforced operant procedure for determining within-session delay discounting functions in rhesus monkeys","volume":"66","author":"Maguire","year":"2012","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/pharmrev.121.000506_bib235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/B978-0-444-59489-1.00007-0","article-title":"Multiple roles for orexin\/hypocretin in addiction","volume":"198","author":"Mahler","year":"2012","journal-title":"Prog Brain Res"},{"key":"10.1124\/pharmrev.121.000506_bib236","doi-asserted-by":"crossref","first-page":"19778","DOI":"10.1073\/pnas.1115231108","article-title":"Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects","volume":"108","author":"Majumdar","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.121.000506_bib237","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0304-3940(93)90457-V","article-title":"RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats","volume":"156","author":"Maldonado","year":"1993","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.121.000506_bib238","doi-asserted-by":"crossref","first-page":"399","DOI":"10.36076\/ppj.2007\/10\/399","article-title":"National drug control policy and prescription drug abuse: facts and fallacies","volume":"10","author":"Manchikanti","year":"2007","journal-title":"Pain Physician"},{"key":"10.1124\/pharmrev.121.000506_bib239","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1097\/00001756-200212200-00026","article-title":"Hyperalgesia and blunted morphine analgesia in G protein-gated potassium channel subunit knockout mice","volume":"13","author":"Marker","year":"2002","journal-title":"Neuroreport"},{"key":"10.1124\/pharmrev.121.000506_bib240","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1523\/JNEUROSCI.5251-03.2004","article-title":"Spinal G-protein-gated K+ channels formed by GIRK1 and GIRK2 subunits modulate thermal nociception and contribute to morphine analgesia","volume":"24","author":"Marker","year":"2004","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib241","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2013.10.004","article-title":"\u201cEvery \u2018never\u2019 I ever said came true\u201d: transitions from opioid pills to heroin injecting","volume":"25","author":"Mars","year":"2014","journal-title":"Int J Drug Policy"},{"key":"10.1124\/pharmrev.121.000506_bib242","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1037\/a0013597","article-title":"Chronic pain alters drug self-administration: implications for addiction and pain mechanisms","volume":"16","author":"Martin","year":"2008","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib243","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00000542-200702000-00020","article-title":"Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics","volume":"106","author":"Martin","year":"2007","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.121.000506_bib244","series-title":"Dependence assessment studies of narcotic analgesics, in Committee on Problems of Drug Dependence, Minutes of the 28th meeting, National Academy of Sciences","first-page":"4658","article-title":"Appendix 19. Activities of the Addiction Research Center during 1965","author":"Martin","year":"1966"},{"key":"10.1124\/pharmrev.121.000506_bib245","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13543784.2023.2187286","article-title":"The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis","volume":"32","author":"Martinez","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/pharmrev.121.000506_bib246","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.drugalcdep.2009.01.019","article-title":"Pathways between nonmedical opioid use\/dependence and psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"103","author":"Martins","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib247","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ejp.1328","article-title":"Why mu-opioid agonists have less analgesic efficacy in neuropathic pain?","volume":"23","author":"Mart\u00ednez-Navarro","year":"2019","journal-title":"Eur J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib248","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.drugalcdep.2008.06.013","article-title":"Correlates of extramedical use of OxyContin versus other analgesic opioids among the US general population","volume":"99","author":"Martins","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib249","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0304-3959(81)90638-2","article-title":"Problems with the use of oxycodone compound in patients with chronic pain","volume":"11","author":"Maruta","year":"1981","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib250","doi-asserted-by":"crossref","first-page":"107906","DOI":"10.1016\/j.neuropharm.2019.107906","article-title":"Targeting the orexin system for prescription opioid use disorder: orexin-1 receptor blockade prevents oxycodone taking and seeking in rats","volume":"164","author":"Matzeu","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib251","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00213-017-4536-6","article-title":"Oxycodone self-administration in male and female rats","volume":"234","author":"Mavrikaki","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib252","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuroscience.2013.10.062","article-title":"Self administration of oxycodone by adolescent and adult mice affects striatal neurotransmitter receptor gene expression","volume":"258","author":"Mayer-Blackwell","year":"2014","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.121.000506_bib253","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF00421301","article-title":"Punished behavior: increases in responding after d-amphetamine","volume":"41","author":"McKearney","year":"1975","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib254","series-title":"Contemporary Research in Behavioral Pharmacology","first-page":"1","article-title":"Schedule-controlled behavior and the effects of drugs","author":"McKearney","year":"1978"},{"key":"10.1124\/pharmrev.121.000506_bib255","article-title":"Opioids for neuropathic pain","volume":"2013","author":"McNicol","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000506_bib256","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.pbb.2004.12.002","article-title":"A preclinical comparison between different opioids: antinociceptive versus adverse effects","volume":"80","author":"Meert","year":"2005","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib257","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000338049","article-title":"Combination of tramadol with minocycline exerted synergistic effects on a rat model of nerve injury-induced neuropathic pain","volume":"21","author":"Mei","year":"2013","journal-title":"Neurosignals"},{"key":"10.1124\/pharmrev.121.000506_bib258","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1097\/AJP.0b013e3181ecd895","article-title":"Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study","volume":"26","author":"Mercadante","year":"2010","journal-title":"Clin J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib259","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J Comp Neurol"},{"key":"10.1124\/pharmrev.121.000506_bib260","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.neubiorev.2021.10.026","article-title":"A novel approach to treating opioid use disorders: dual agonists of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors","volume":"131","author":"Merkel","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1124\/pharmrev.121.000506_bib261","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/npp.2017.70","article-title":"Effects of ibudilast on the subjective, reinforcing, and analgesic effects of oxycodone in recently detoxified adults with opioid dependence","volume":"42","author":"Metz","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib262","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1254\/jphs.09139FP","article-title":"Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models","volume":"111","author":"Minami","year":"2009","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000506_bib263","doi-asserted-by":"crossref","first-page":"173241","DOI":"10.1016\/j.pbb.2021.173241","article-title":"Minocycline attenuates oxycodone-induced positive subjective responses in non-dependent, recreational opioid users","volume":"209","author":"Mogali","year":"2021","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib264","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41583-020-0310-6","article-title":"Qualitative sex differences in pain processing: emerging evidence of a biased literature","volume":"21","author":"Mogil","year":"2020","journal-title":"Nat Rev Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0306-4522(96)00338-7","article-title":"Orphanin FQ is a functional anti-opioid peptide","volume":"75","author":"Mogil","year":"1996","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.121.000506_bib266","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0024-3205(99)00148-4","article-title":"Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans","volume":"64","author":"Monory","year":"1999","journal-title":"Life Sci"},{"key":"10.1124\/pharmrev.121.000506_bib267","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/B978-0-323-91534-2.00003-5","article-title":"The pathophysiology of opioid-induced respiratory depression","volume":"188","author":"Montandon","year":"2022","journal-title":"Handb Clin Neurol"},{"key":"10.1124\/pharmrev.121.000506_bib268","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3389\/fnins.2016.00471","article-title":"BOLD imaging in awake wild-type and mu-opioid receptor knock-out mice reveals on-target activation maps in response to oxycodone","volume":"10","author":"Moore","year":"2016","journal-title":"Front Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib269","doi-asserted-by":"crossref","first-page":"262","DOI":"10.5812\/aapm.4529","article-title":"Use of oxycodone in pain management","volume":"1","author":"Moradi","year":"2012","journal-title":"Anesth Pain Med"},{"key":"10.1124\/pharmrev.121.000506_bib270","unstructured":"Muhuri PK, Gfroerer JC, Davies MC (2013) Associations of nonmedical pain reliever use and initiation of heroin use in the United States. CBHSQ Data Review, SAMHSA, https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/DR006\/DR006\/nonmedical-pain-reliever-use-2013.htm"},{"key":"10.1124\/pharmrev.121.000506_bib273","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1471-4159.1999.0730179.x","article-title":"Orphanin FQ\/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis","volume":"73","author":"Murphy","year":"1999","journal-title":"J Neurochem"},{"key":"10.1124\/pharmrev.121.000506_bib274","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/35012069","article-title":"Rewarding effects of opiates are absent in mice lacking the receptor for substance P","volume":"405","author":"Murtra","year":"2000","journal-title":"Nature"},{"key":"10.1124\/pharmrev.121.000506_bib275","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1749-6632.1992.tb25982.x","article-title":"Behavioral and pharmacological determinants of drug abuse","volume":"654","author":"Nader","year":"1992","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/pharmrev.121.000506_bib276","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/bph.12441","article-title":"G protein-gated inwardly rectifying potassium (KIR3) channels play a primary role in the antinociceptive effect of oxycodone, but not morphine, at supraspinal sites","volume":"171","author":"Nakamura","year":"2014","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib277","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1476-5381.2012.02139.x","article-title":"Differential activation of the \u03bc-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model","volume":"168","author":"Nakamura","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib278","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.npp.1301471","article-title":"Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine","volume":"33","author":"Narita","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib279","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1021\/acsptsci.9b00021","article-title":"Oxycodone-mediated activation of the mu opioid receptor reduces whole brain functional connectivity in mice","volume":"2","author":"Nasseef","year":"2019","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1124\/pharmrev.121.000506_bib280","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.pbb.2012.07.001","article-title":"Post-injury repeated administrations of minocycline improve the antinociceptive effect of morphine in chronic constriction injury model of neuropathic pain in rat","volume":"102","author":"Nazemi","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib281","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1021\/acschemneuro.6b00413","article-title":"Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats","volume":"8","author":"Neelakantan","year":"2017","journal-title":"ACS Chem Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib282","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1037\/pha0000028","article-title":"Discriminative stimulus effects of morphine and oxycodone in the absence and presence of acetic acid in male and female C57Bl\/6 mice","volume":"23","author":"Neelakantan","year":"2015","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib283","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1021\/acs.jmedchem.9b01105","article-title":"2016 Philip S. Portoghese Medicinal Chemistry Lectureship: designing bivalent or bitopic molecules for G-protein coupled receptors. The whole is greater than the sum of its parts","volume":"63","author":"Newman","year":"2020","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.121.000506_bib284","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bcp.2012.06.023","article-title":"Medication discovery for addiction: translating the dopamine D3 receptor hypothesis","volume":"84","author":"Newman","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib285","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neuropharm.2019.04.010","article-title":"\u03949-tetrahydrocannabinol attenuates oxycodone self-administration under extended access conditions","volume":"151","author":"Nguyen","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib286","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1111\/bph.15520","article-title":"Paradoxical changes in brain reward status during oxycodone self-administration in a novel test of the negative reinforcement hypothesis","volume":"178","author":"Nguyen","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib287","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.neuropharm.2018.06.026","article-title":"Prophylactic vaccination protects against the development of oxycodone self-administration","volume":"138","author":"Nguyen","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib288","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1124\/pharmrev.121.000367","article-title":"Sex differences in opioid and psychostimulant craving and relapse: a critical review","volume":"74","author":"Nicolas","year":"2022","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000506_bib289","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2007.03.022","article-title":"Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain","volume":"132","author":"Nielsen","year":"2007","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-3565(24)38873-1","article-title":"Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat","volume":"295","author":"Nielsen","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib291","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2005.09.051","article-title":"Antinociceptive effect of oxycodone in diabetic mice","volume":"524","author":"Nozaki","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib292","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neulet.2004.01.056","article-title":"Local peripheral effects of \u03bc-opioid receptor agonists in neuropathic pain in rats","volume":"360","author":"Obara","year":"2004","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.121.000506_bib293","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/bs.irn.2016.02.009","article-title":"Animal models and the development of vaccines to treat substance use disorders","volume":"126","author":"Ohia-Nwoko","year":"2016","journal-title":"Int Rev Neurobiol"},{"key":"10.1124\/pharmrev.121.000506_bib294","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1056\/NEJMp1011512","article-title":"A flood of opioids, a rising tide of deaths","volume":"363","author":"Okie","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1124\/pharmrev.121.000506_bib295","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1124\/dmd.108.022087","article-title":"Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone","volume":"36","author":"Okura","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/pharmrev.121.000506_bib296","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tips.2013.02.001","article-title":"Does the pharmacology of oxycodone justify its increasing use as an analgesic?","volume":"34","author":"Olkkola","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000506_bib297","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s00213-005-0022-7","article-title":"Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats","volume":"181","author":"Olmstead","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib298","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217371","article-title":"Comprehensive molecular pharmacology screening reveals potential new receptor interactions for clinically relevant opioids","volume":"14","author":"Olson","year":"2019","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.121.000506_bib299","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000143223","article-title":"Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes","volume":"74","author":"Ong","year":"2008","journal-title":"Oncology"},{"key":"10.1124\/pharmrev.121.000506_bib300","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12094-007-0057-9","article-title":"Oxycodone: a pharmacological and clinical review","volume":"9","author":"Ord\u00f3\u00f1ez Gallego","year":"2007","journal-title":"Clin Transl Oncol"},{"key":"10.1124\/pharmrev.121.000506_bib301","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0304-3940(95)12026-Z","article-title":"Inhibition by spinal morphine of the tail-flick response is attenuated in rats with nerve ligation injury","volume":"199","author":"Ossipov","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1124\/pharmrev.121.000506_bib302","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/clpt.1993.43","article-title":"Inhibition by fluoxetine of cytochrome P450 2D6 activity","volume":"53","author":"Otton","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib303","doi-asserted-by":"crossref","first-page":"108439","DOI":"10.1016\/j.neuropharm.2020.108439","article-title":"Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain","volume":"185","author":"Pantouli","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib304","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00213-009-1558-8","article-title":"Acute effects of morphine on distinct forms of impulsive behavior in rats","volume":"205","author":"Pattij","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib305","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.brainres.2005.07.060","article-title":"Comparison of the antinociceptive effect of acute morphine in female and male Sprague-Dawley rats using the long-lasting mu-antagonist methocinnamox","volume":"1058","author":"Peckham","year":"2005","journal-title":"Brain Res"},{"key":"10.1124\/pharmrev.121.000506_bib306","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.094276","article-title":"Comparison of the antinociceptive response to morphine and morphine-like compounds in male and female Sprague-Dawley rats","volume":"316","author":"Peckham","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib307","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-008-1173-0","article-title":"The role of impulsive behavior in drug abuse","volume":"200","author":"Perry","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib308","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1073\/pnas.70.8.2243","article-title":"Properties of opiate-receptor binding in rat brain","volume":"70","author":"Pert","year":"1973","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.121.000506_bib309","doi-asserted-by":"crossref","DOI":"10.1111\/adb.12828","article-title":"Oral prescription opioid-seeking behavior in male and female mice","volume":"25","author":"Phillips","year":"2020","journal-title":"Addict Biol"},{"key":"10.1124\/pharmrev.121.000506_bib310","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.drudis.2011.08.006","article-title":"Pharmacogenetics: past, present and future","volume":"16","author":"Pirmohamed","year":"2011","journal-title":"Drug Discov Today"},{"key":"10.1124\/pharmrev.121.000506_bib311","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1901\/jeab.2005.47-04","article-title":"Effects of methylphenidate and morphine on delay-discount functions obtained within sessions","volume":"83","author":"Pitts","year":"2005","journal-title":"J Exp Anal Behav"},{"key":"10.1124\/pharmrev.121.000506_bib312","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1093\/scan\/nsz077","article-title":"Transition to substance use disorders: impulsivity for reward and learning from reward","volume":"15","author":"Poulton","year":"2020","journal-title":"Soc Cogn Affect Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib313","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-0773.1992.tb00441.x","article-title":"Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats","volume":"70","author":"P\u00f6yhi\u00e4","year":"1992","journal-title":"Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.121.000506_bib314","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2125.1991.tb03942.x","article-title":"The pharmacokinetics of oxycodone after intravenous injection in adults","volume":"32","author":"P\u00f6yhi\u00e4","year":"1991","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib315","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2125.1992.tb04090.x","article-title":"The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects","volume":"33","author":"P\u00f6yhi\u00e4","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib316","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0885-3924(93)90101-Z","article-title":"A review of oxycodone\u2019s clinical pharmacokinetics and pharmacodynamics","volume":"8","author":"P\u00f6yhi\u00e4","year":"1993","journal-title":"J Pain Symptom Manage"},{"key":"10.1124\/pharmrev.121.000506_bib317","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1080\/21645515.2016.1212785","article-title":"Biologics to treat substance use disorders: current status and new directions","volume":"12","author":"Pravetoni","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1124\/pharmrev.121.000506_bib318","doi-asserted-by":"crossref","first-page":"107662","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat opioid use disorders and reduce incidence of overdose","volume":"158","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib319","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib320","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/jm3013745","article-title":"Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens","volume":"56","author":"Pravetoni","year":"2013","journal-title":"J Med Chem"},{"key":"10.1124\/pharmrev.121.000506_bib321","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101807","article-title":"Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000506_bib322","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-2999(01)01308-5","article-title":"Opioids in chronic pain","volume":"429","author":"Przew\u0142ocki","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib323","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1471-4159.2007.04812.x","article-title":"RGS9-2 is a negative modulator of mu-opioid receptor function","volume":"103","author":"Psifogeorgou","year":"2007","journal-title":"J Neurochem"},{"key":"10.1124\/pharmrev.121.000506_bib324","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1523\/JNEUROSCI.4146-10.2011","article-title":"A unique role of RGS9-2 in the striatum as a positive or negative regulator of opiate analgesia","volume":"31","author":"Psifogeorgou","year":"2011","journal-title":"J Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib325","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.neuropharm.2010.08.003","article-title":"The role of beta-arrestin2 in the severity of antinociceptive tolerance and physical dependence induced by different opioid pain therapeutics","volume":"60","author":"Raehal","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib326","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1124\/jpet.120.000014","article-title":"Combining a candidate vaccine for opioid use disorders with extended-release naltrexone increases protection against oxycodone-induced behavioral effects and toxicity","volume":"374","author":"Raleigh","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib327","doi-asserted-by":"crossref","first-page":"108653","DOI":"10.1016\/j.neuropharm.2021.108653","article-title":"Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder","volume":"195","author":"Raleigh","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib328","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.117.247049","article-title":"Opioid dose- and route-dependency of oxycodone and heroin vaccines in rats","volume":"365","author":"Raleigh","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib329","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse","volume":"12","author":"Raleigh","year":"2017","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.121.000506_bib330","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.neuroscience.2019.04.047","article-title":"Sex differences in neuroplasticity- and stress related gene expression and protein levels in the rat hippocampus following oxycodone conditioned place preference","volume":"410","author":"Randesi","year":"2019","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.121.000506_bib331","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1124\/jpet.103.060582","article-title":"Loss of peripheral morphine analgesia contributes to the reduced effectiveness of systemic morphine in neuropathic pain","volume":"309","author":"Rashid","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib332","series-title":"Goodman and Gilman\u2019s the Pharmacological Basis of Therapeutics","first-page":"521","article-title":"Opioid analgesics and antagonists","author":"Reisine","year":"1996"},{"key":"10.1124\/pharmrev.121.000506_bib333","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11916-019-0751-7","article-title":"Oxycodone\u2019s unparalleled addictive potential: is it time for a moratorium?","volume":"23","author":"Remillard","year":"2019","journal-title":"Curr Pain Headache Rep"},{"key":"10.1124\/pharmrev.121.000506_bib334","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-0270(95)00153-0","article-title":"Progressive ratio schedules in drug self-administration studies in rats: a method to evaluate reinforcing efficacy","volume":"66","author":"Richardson","year":"1996","journal-title":"J Neurosci Methods"},{"key":"10.1124\/pharmrev.121.000506_bib335","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1185\/030079908X253708","article-title":"Oxycodone: a review of its use in the management of pain","volume":"24","author":"Riley","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1124\/pharmrev.121.000506_bib336","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0304-3959(97)00199-1","article-title":"Sex differences in the perception of noxious experimental stimuli: a meta-analysis","volume":"74","author":"Riley","year":"1998","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib337","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0028-3908(02)00295-2","article-title":"Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors","volume":"43","author":"Ripley","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib338","series-title":"Handbook of Psychopharmacology Vol. 17","first-page":"13","article-title":"Opiate receptors","author":"Robson","year":"1983"},{"key":"10.1124\/pharmrev.121.000506_bib339","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00000542-200503000-00008","article-title":"Polymorphism of \u03bc-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response","volume":"102","author":"Romberg","year":"2005","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.121.000506_bib340","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0304-3959(97)00093-6","article-title":"The intrinsic antinociceptive effects of oxycodone appear to be \u03ba-opioid receptor mediated","volume":"73","author":"Ross","year":"1997","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib341","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.pain.2013.05.004","article-title":"Buprenorphine\/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone","volume":"154","author":"Roux","year":"2013","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib342","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.anclin.2017.01.022","article-title":"Revisiting oxycodone analgesia: a review and hypothesis","volume":"35","author":"Ruan","year":"2017","journal-title":"Anesthesiol Clin"},{"key":"10.1124\/pharmrev.121.000506_bib343","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neuroscience.2018.10.002","article-title":"Sex differences in the rat hippocampal opioid system after oxycodone conditioned place preference","volume":"393","author":"Ryan","year":"2018","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.121.000506_bib344","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2010.07.036","article-title":"Effects of the NOP receptor agonist Ro65-6570 on the acquisition of opiate- and psychostimulant-induced conditioned place preference in rats","volume":"645","author":"Rutten","year":"2010","journal-title":"Eur J Pharmacol"},{"issue":"Spec No. 2","key":"10.1124\/pharmrev.121.000506_bib345","doi-asserted-by":"crossref","first-page":"R207","DOI":"10.1093\/hmg\/ddi261","article-title":"Pharmacogenetics\/genomics and personalized medicine","volume":"14","author":"Sad\u00e9e","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1124\/pharmrev.121.000506_bib346","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1124\/pharmrev.122.000810","article-title":"Pharmacogenomics: driving personalized medicine","volume":"75","author":"Sad\u00e9e","year":"2023","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000506_bib347","doi-asserted-by":"crossref","first-page":"617973","DOI":"10.3389\/fnins.2020.617973","article-title":"Prolonged withdrawal from escalated oxycodone is associated with increased expression of glutamate receptors in the rat hippocampus","volume":"14","author":"Salisbury","year":"2021","journal-title":"Front Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib348","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1476-5381.2010.00709.x","article-title":"Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety","volume":"160","author":"Samer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib349","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1476-5381.2010.00673.x","article-title":"The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone","volume":"160","author":"Samer","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib350","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13241","article-title":"Intermittent access to oxycodone decreases dopamine uptake in the nucleus accumbens core during abstinence","volume":"27","author":"Samson","year":"2022","journal-title":"Addict Biol"},{"key":"10.1124\/pharmrev.121.000506_bib351","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1007\/s00213-016-4425-4","article-title":"Long-lasting effects of adolescent oxycodone exposure on reward-related behavior and gene expression in mice","volume":"233","author":"Sanchez","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib352","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/mp.2017.102","article-title":"Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential","volume":"23","author":"Sandweiss","year":"2018","journal-title":"Mol Psychiatry"},{"key":"10.1124\/pharmrev.121.000506_bib353","first-page":"83","article-title":"The DEA perspective on prescription drug diversion and abuse","volume":"183","author":"Sapienza","year":"2003","journal-title":"Proceedings of the 64th annual scientific meeting. The College on Problems of Drug Dependence NIDA Research Monograph"},{"key":"10.1124\/pharmrev.121.000506_bib354","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.113.210799","article-title":"The neurokinin-1 receptor in addictive processes","volume":"351","author":"Schank","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib355","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1124\/pharmrev.121.000506_bib356","article-title":"Oxycodone for cancer-related pain","volume":"8","author":"Schmidt-Hansen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1124\/pharmrev.121.000506_bib357","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2019.01.020","article-title":"Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female rats","volume":"150","author":"Schwienteck","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib358","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0022-3565(25)04686-5","article-title":"Opiate addiction in the monkey I. Methods of study","volume":"56","author":"Seevers","year":"1936","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib359","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.ssmph.2020.100679","article-title":"The economic underpinnings of the drug epidemic","volume":"12","author":"Seltzer","year":"2020","journal-title":"SSM Popul Health"},{"key":"10.1124\/pharmrev.121.000506_bib360","first-page":"942","article-title":"Probable relationship between opioid abuse and heroin use","volume":"67","author":"Siegal","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1124\/pharmrev.121.000506_bib361","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/0091-3057(92)90382-P","article-title":"Effect of stress on oral morphine and fentanyl self-administration in rats","volume":"41","author":"Shaham","year":"1992","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib362","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0091-3057(93)90359-2","article-title":"Effect of stress on oral fentanyl consumption in rats in an operant self-administration paradigm","volume":"46","author":"Shaham","year":"1993","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib363","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/BF02249346","article-title":"Exposure to mild stress enhances the reinforcing efficacy of intravenous heroin self-administration in rats","volume":"114","author":"Shaham","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib365","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/j.1399-6576.1998.tb05169.x","article-title":"Comparison of analgesic efficacy of oxycodone and morphine in postoperative intravenous patient-controlled analgesia","volume":"42","author":"Silvasti","year":"1998","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1124\/pharmrev.121.000506_bib366","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1067\/mcp.2003.5","article-title":"Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers","volume":"73","author":"Skarke","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/pharmrev.121.000506_bib367","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.tips.2015.07.002","article-title":"Biologic approaches to treat substance-use disorders","volume":"36","author":"Skolnick","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000506_bib368","doi-asserted-by":"crossref","DOI":"10.1111\/adb.13253","article-title":"Oral oxycodone self-administration leads to features of opioid misuse in male and female mice","volume":"28","author":"Slivicki","year":"2023","journal-title":"Addict Biol"},{"key":"10.1124\/pharmrev.121.000506_bib369","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/01.anes.0000265176.75372.ed","article-title":"Oxycodone\u2019s mechanism of action and potency differences after spinal and systemic routes of administration","volume":"106","author":"Smith","year":"2007","journal-title":"Anesthesiology"},{"key":"10.1124\/pharmrev.121.000506_bib370","series-title":"Drug Discovery: A History","author":"Sneader","year":"2005"},{"key":"10.1124\/pharmrev.121.000506_bib371","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0022-3565(25)28956-X","article-title":"Quantitative determination of morphine in serum by radioimmunoassay","volume":"178","author":"Spector","year":"1971","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib372","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0031-6997(25)06605-0","article-title":"Antibodies to morphine, barbiturates, and serotonin","volume":"25","author":"Spector","year":"1973","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.121.000506_bib373","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1126\/science.168.3937.1347","article-title":"Morphine: radioimmunoassay","volume":"168","author":"Spector","year":"1970","journal-title":"Science"},{"key":"10.1124\/pharmrev.121.000506_bib374","first-page":"68","article-title":"Changing patterns in opioid addiction. Characterizing users of oxycodone and other opioids","volume":"55","author":"Sproule","year":"2009","journal-title":"Can Family Physician"},{"key":"10.1124\/pharmrev.121.000506_bib375","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3758\/BF03331967","article-title":"Ovarian hormones do not affect the initiation and maintenances of intravenous self-administration of heroin in the female rat","volume":"24","author":"Stewart","year":"1996","journal-title":"Psychobiology (Austin Tex)"},{"key":"10.1124\/pharmrev.121.000506_bib376","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00213-010-1942-4","article-title":"Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies","volume":"212","author":"Stoops","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib377","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1211\/0022357011775622","article-title":"Antinociceptive effect of U-50488H, a \u03ba-opioid agonist, in streptozotocin-induced diabetic mice","volume":"53","author":"Suzuki","year":"2001","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib378","first-page":"614","article-title":"Evaluation of new compounds for morphine-like physical dependence in the rhesus monkey","author":"Swain","year":"1977","journal-title":"Proceedings of the Thirty Ninth Annual Meeting of the Committee on Problems of Drug Dependence"},{"key":"10.1124\/pharmrev.121.000506_bib379","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.vascn.2016.05.011","article-title":"Drug discrimination: a versatile tool for characterization of CNS safety pharmacology and potential for drug abuse","volume":"81","author":"Swedberg","year":"2016","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/pharmrev.121.000506_bib380","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/bph.13039","article-title":"Enhanced GABAergic synaptic transmission at VLPAG neurons and potent modulation by oxycodone in a bone cancer pain model","volume":"172","author":"Takasu","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib381","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0952-8180(97)00147-5","article-title":"Comparison of respiratory effects of tramadol and oxycodone","volume":"9","author":"Tarkkila","year":"1997","journal-title":"J Clin Anesth"},{"key":"10.1124\/pharmrev.121.000506_bib382","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0022-3565(25)04096-0","article-title":"Morphine addiction and its physiological interpretation based on experimental evidences","volume":"36","author":"Tatum","year":"1929","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib383","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.103.058602","article-title":"Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at \u03bc- and \u03b4-opioid receptors","volume":"308","author":"Thompson","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/pharmrev.121.000506_bib384","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00213-017-4599-4","article-title":"Tolerance and cross-tolerance to the antinociceptive effects of oxycodone and the imidazoline I2 receptor agonist phenyzoline in adult male rats","volume":"234","author":"Thorn","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib385","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s40263-020-00722-8","article-title":"Preclinical evaluation of vaccines to treat opioid use disorders: how close are we to a clinically viable therapeutic?","volume":"34","author":"Townsend","year":"2020","journal-title":"CNS Drugs"},{"key":"10.1124\/pharmrev.121.000506_bib386","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00213-017-4652-3","article-title":"Effects of nalfurafine on oxycodone reinforcement, thermal antinociception and respiration: modeling an abuse-deterrent opioid analgesic in rats","volume":"234","author":"Townsend","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib387","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.tips.2008.11.006","article-title":"RGS9-2: probing an intracellular modulator of behavior as a drug target","volume":"30","author":"Traynor","year":"2009","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/pharmrev.121.000506_bib388","doi-asserted-by":"crossref","first-page":"120098","DOI":"10.1016\/j.jns.2021.120098","article-title":"Current status of vaccines for substance use disorders: a brief review of human studies","volume":"434","author":"Truong","year":"2022","journal-title":"J Neurol Sci"},{"key":"10.1124\/pharmrev.121.000506_bib389","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2217\/pgs-2020-0143","article-title":"Pharmacogenomics of oxycodone: a narrative literature review","volume":"22","author":"Umukoro","year":"2021","journal-title":"Pharmacogenomics"},{"key":"10.1124\/pharmrev.121.000506_bib390","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-3959(95)00214-6","article-title":"Gender variations in clinical pain experience","volume":"65","author":"Unruh","year":"1996","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib391","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.pain.2013.10.027","article-title":"Higher pain perception and lack of recovery from neuropathic pain in females: a behavioural, immunohistochemical, and proteomic investigation on sex-related differences in mice","volume":"155","author":"Vacca","year":"2014","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib392","first-page":"1","article-title":"Drug addiction: medical and social aspects in France","volume":"2","author":"Vaille","year":"1954","journal-title":"Bull Narcotics"},{"key":"10.1124\/pharmrev.121.000506_bib393","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1093\/bja\/aex295","article-title":"An experimental study comparing the respiratory effects of tapentadol and oxycodone in healthy volunteers","volume":"119","author":"van der Schrier","year":"2017","journal-title":"Br J Anaesth"},{"key":"10.1124\/pharmrev.121.000506_bib394","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1046\/j.1360-0443.1999.949141312.x","article-title":"Male-female differences in the earliest stages of drug involvement","volume":"94","author":"Van Etten","year":"1999","journal-title":"Addiction"},{"key":"10.1124\/pharmrev.121.000506_bib395","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1089\/15246090152636550","article-title":"Male-female differences in transitions from first drug opportunity to first use: searching for subgroup variation by age, race, region, and urban status","volume":"10","author":"Van Etten","year":"2001","journal-title":"J Womens Health Gend Based Med"},{"key":"10.1124\/pharmrev.121.000506_bib396","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1111\/ejn.12709","article-title":"Rapid dopamine transmission within the nucleus accumbens: dramatic difference between morphine and oxycodone delivery","volume":"40","author":"Vander Weele","year":"2014","journal-title":"Eur J Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib397","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/bph.15760","article-title":"Strategies towards safer opioid analgesics\u2014a review of old and upcoming targets","volume":"180","author":"Varga","year":"2023","journal-title":"Br J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib398","doi-asserted-by":"crossref","first-page":"882491","DOI":"10.3389\/fpsyt.2022.882491","article-title":"Current trends and perspectives in the immune therapy for substance use disorders","volume":"13","author":"Vasiliu","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1124\/pharmrev.121.000506_bib399","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.pbr.2015.08.004","article-title":"Animal models of drug relapse and craving: From drug priming-induced reinstatement to incubation of craving after voluntary abstinence","volume":"224","author":"Venniro","year":"2016","journal-title":"Prog Brain Res"},{"key":"10.1124\/pharmrev.121.000506_bib400","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/7854_2014_344","article-title":"The self-administration of analgesic drugs in experimentally induced chronic pain","volume":"20","author":"Wade","year":"2014","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1124\/pharmrev.121.000506_bib401","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/npp.2014.188","article-title":"Compulsive-like responding for opioid analgesics in rats with extended access","volume":"40","author":"Wade","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib402","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.neuropharm.2019.02.007","article-title":"Oxycodone-like discriminative stimulus effects of fentanyl-related emerging drugs of abuse in mice","volume":"150","author":"Walentiny","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib403","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.drugalcdep.2018.02.035","article-title":"Nociceptin\/orphanin FQ receptors modulate the discriminative stimulus effects of oxycodone in C57BL\/6 mice","volume":"187","author":"Walentiny","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib404","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1369-1600.2011.00419.x","article-title":"Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers","volume":"18","author":"Walsh","year":"2013","journal-title":"Addict Biol"},{"key":"10.1124\/pharmrev.121.000506_bib405","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.drugalcdep.2008.05.007","article-title":"The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers","volume":"98","author":"Walsh","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib406","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.cell.2022.12.026","article-title":"Structures of the entire human opioid receptor family","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1124\/pharmrev.121.000506_bib407","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/WNL.50.6.1837","article-title":"Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia","volume":"50","author":"Watson","year":"1998","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.121.000506_bib408","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","article-title":"Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy","volume":"105","author":"Watson","year":"2003","journal-title":"Pain"},{"key":"10.1124\/pharmrev.121.000506_bib409","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40429-014-0035-6","article-title":"Recent translational findings on impulsivity in relation to drug abuse","volume":"1","author":"Weafer","year":"2014","journal-title":"Curr Addict Rep"},{"key":"10.1124\/pharmrev.121.000506_bib410","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1007\/s12325-020-01481-0","article-title":"A phase I placebo-controlled trial comparing the effects of buprenorphine buccal film and oral oxycodone hydrochloride administration on respiratory drive","volume":"37","author":"Webster","year":"2020","journal-title":"Adv Ther"},{"key":"10.1124\/pharmrev.121.000506_bib411","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1574884716666210225083213","article-title":"Ventilatory response to hypercapnia as experimental model to study effects of oxycodone on respiration depressions","volume":"17","author":"Webster","year":"2022","journal-title":"Curr Rev Clin Exp Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib412","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5055\/jom.2011.0066","article-title":"Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain","volume":"7","author":"Webster","year":"2011","journal-title":"J Opioid Manag"},{"key":"10.1124\/pharmrev.121.000506_bib413","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","article-title":"Mechanisms of fatal opioid overdose","volume":"94","author":"White","year":"1999","journal-title":"Addiction"},{"key":"10.1124\/pharmrev.121.000506_bib414","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s13181-012-0263-x","article-title":"Likeability and abuse liability of commonly prescribed opioids","volume":"8","author":"Wightman","year":"2012","journal-title":"J Med Toxicol"},{"key":"10.1124\/pharmrev.121.000506_bib415","doi-asserted-by":"crossref","first-page":"107778","DOI":"10.1016\/j.drugalcdep.2019.107778","article-title":"Discrimination learning in oxycodone-treated nonhuman primates","volume":"207","author":"Withey","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib416","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jpain.2018.02.003","article-title":"Concurrent assessment of the antinociceptive and behaviorally disruptive effects of opioids in squirrel monkeys","volume":"19","author":"Withey","year":"2018","journal-title":"J Pain"},{"key":"10.1124\/pharmrev.121.000506_bib417","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1172\/JCI101169","article-title":"Measurement of the effect of morphine, codeine, and other opiates on the pain threshold and analysis of their relation to the pain experience","volume":"19","author":"Wolff","year":"1940","journal-title":"J Clin Invest"},{"key":"10.1124\/pharmrev.121.000506_bib418","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s11864-022-01010-x","article-title":"The role of pharmacogenomics in opioid prescribing","volume":"23","author":"Wong","year":"2022","journal-title":"Curr Treat Options in Oncol"},{"key":"10.1124\/pharmrev.121.000506_bib419","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-023-01590-8","article-title":"Effects of selective dopamine D3 receptor partial agonist\/antagonists on oxycodone self-administration and antinociception in monkeys","author":"Woodlief","year":"2023","journal-title":"Neuropsychopharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib420","first-page":"83","article-title":"Evaluation of new compounds for opioid activity","volume":"183","author":"Woods","year":"2003","journal-title":"Proceedings of the 64th annual scientific meeting. The College on Problems of Drug Dependence NIDA Research Monograph"},{"key":"10.1124\/pharmrev.121.000506_bib421","doi-asserted-by":"crossref","first-page":"ra63","DOI":"10.1126\/scisignal.2002922","article-title":"The complex of G protein regulator RGS9-2 and G\u03b2(5) controls sensitization and signaling kinetics of type 5 adenylyl cyclase in the striatum","volume":"5","author":"Xie","year":"2012","journal-title":"Sci Signal"},{"key":"10.1124\/pharmrev.121.000506_bib422","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.toxrep.2020.01.008","article-title":"Developing an animal model to detect drug-drug interactions impacting drug-induced respiratory depression","volume":"7","author":"Xu","year":"2020","journal-title":"Toxicol Rep"},{"key":"10.1124\/pharmrev.121.000506_bib423","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/cts.13080","article-title":"Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat","volume":"14","author":"Xu","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1124\/pharmrev.121.000506_bib424","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejphar.2019.04.009","article-title":"Delta-opioid receptor antagonist naltrindole reduces oxycodone addiction and constipation in mice","volume":"852","author":"Yang","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib425","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.phrs.2016.05.034","article-title":"Activation of delta-opioid receptor contributes to the antinociceptive effect of oxycodone in mice","volume":"111","author":"Yang","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1124\/pharmrev.121.000506_bib426","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/bja\/aeh218","article-title":"Epidural oxycodone or morphine following gynaecological surgery","volume":"93","author":"Yanagidate","year":"2004","journal-title":"Br J Anaesth"},{"key":"10.1124\/pharmrev.121.000506_bib427","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrd.2017.87","article-title":"Breaking barriers to novel analgesic drug development","volume":"16","author":"Yekkirala","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/pharmrev.121.000506_bib428","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0091-3057(94)00375-S","article-title":"Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity","volume":"51","author":"Yoburn","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib429","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41386-018-0284-5","article-title":"Dopamine D3R antagonist VK4-116 attenuates oxycodone self-administration and reinstatement without compromising its antinociceptive effects","volume":"44","author":"You","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib430","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2017.09.007","article-title":"The novel dopamine D3 receptor antagonists\/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats","volume":"126","author":"You","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib431","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3389\/fpsyt.2018.00257","article-title":"Oxycodone self-administration induces alterations in expression of integrin, semaphoring and ephrin genes in the mouse striatum","volume":"9","author":"Yuferov","year":"2018","journal-title":"Front Psychiatry"},{"key":"10.1124\/pharmrev.121.000506_bib432","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/ajhp\/58.13.1175","article-title":"Federal reports say oxycodone abuse is on the rise","volume":"58","author":"Young","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1124\/pharmrev.121.000506_bib433","doi-asserted-by":"crossref","first-page":"13656","DOI":"10.1073\/pnas.2232594100","article-title":"Essential role for RGS9 in opiate action","volume":"100","author":"Zachariou","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/pharmrev.121.000506_bib434","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0376-8716(03)00003-6","article-title":"College on Problems of Drug Dependence Taskforce on Prescription Opioid Non-Medical Use And Abuse: position statement","volume":"69","author":"Zacny","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib435","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pbb.2009.07.010","article-title":"The prescription opioid, oxycodone, does not alter behavioral measures of impulsivity in healthy volunteers","volume":"94","author":"Zacny","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/pharmrev.121.000506_bib436","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.drugalcdep.2009.10.012","article-title":"Psychopharmacological effects of oxycodone in healthy volunteers: roles of alcohol-drinking status and sex","volume":"107","author":"Zacny","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib437","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00213-003-1540-9","article-title":"Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers","volume":"170","author":"Zacny","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib438","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.drugalcdep.2008.11.013","article-title":"Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers","volume":"101","author":"Zacny","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib439","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1037\/a0022952","article-title":"Psychopharmacological effects of oxycodone in volunteers with and without generalized anxiety disorder","volume":"19","author":"Zacny","year":"2011","journal-title":"Exp Clin Psychopharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib440","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00213-007-0937-2","article-title":"Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers","volume":"196","author":"Zacny","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib441","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0376-8716(96)01274-4","article-title":"The effects of a cold-water immersion stressor on the reinforcing and subjective effects of fentanyl in healthy volunteers","volume":"42","author":"Zacny","year":"1996","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib442","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.drugalcdep.2018.08.002","article-title":"The G-protein biased mu-opioid agonist, TRV130, produces reinforcing and antinociceptive effects that are comparable to oxycodone in rats","volume":"192","author":"Zamarripa","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/pharmrev.121.000506_bib443","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00213-020-05473-4","article-title":"Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys","volume":"237","author":"Zamarripa","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib444","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1007\/s00213-021-05965-x","article-title":"The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats","volume":"238","author":"Zamarripa","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib445","doi-asserted-by":"crossref","first-page":"107978","DOI":"10.1016\/j.neuropharm.2020.107978","article-title":"Female and male rats readily consume and prefer oxycodone to water in a chronic, continuous access, two-bottle oral voluntary paradigm","volume":"167","author":"Zanni","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib446","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuroscience.2014.11.013","article-title":"Self administration of oxycodone alters synaptic plasticity gene expression in the hippocampus differentially in male adolescent and adult mice","volume":"285","author":"Zhang","year":"2015","journal-title":"Neuroscience"},{"key":"10.1124\/pharmrev.121.000506_bib447","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41386-019-0531-4","article-title":"Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats","volume":"45","author":"Zhang","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib448","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1007\/s00213-017-4657-y","article-title":"Alterations of expression of inflammation\/immune-related genes in the dorsal and ventral striatum of adult C57BL\/6J mice following chronic oxycodone self-administration: a RNA sequencing study","volume":"234","author":"Zhang","year":"2017","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib449","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s00213-013-3306-3","article-title":"Extended access oxycodone self-administration and neurotransmitter receptor gene expression in the dorsal striatum of adult C57BL\/6 J mice","volume":"231","author":"Zhang","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/pharmrev.121.000506_bib450","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/npp.2008.134","article-title":"Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice","volume":"34","author":"Zhang","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib451","doi-asserted-by":"crossref","first-page":"108599","DOI":"10.1016\/j.neuropharm.2021.108599","article-title":"A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats","volume":"192","author":"Zhang","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1124\/pharmrev.121.000506_bib452","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1038\/s41380-020-01011-y","article-title":"Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses","volume":"26","author":"Zhou","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1124\/pharmrev.121.000506_bib453","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1212\/WNL.60.6.894","article-title":"An old acquaintance: opioids in neuropathic pain","volume":"60","author":"Zochodne","year":"2003","journal-title":"Neurology"},{"key":"10.1124\/pharmrev.121.000506_bib454","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/0091270010397729","article-title":"Lack of association of OPRM1 and ABCB1 single-nucleotide polymorphisms to oxycodone response in postoperative pain","volume":"52","author":"Zwisler","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/pharmrev.121.000506_bib455","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1472-8206.2009.00781.x","article-title":"The antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genes","volume":"24","author":"Zwisler","year":"2010","journal-title":"Fundam Clin Pharmacol"}],"updated-by":[{"DOI":"10.1124\/pharmrev.121.000506err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000}}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724007956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724007956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.121.000506","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T04:41:02Z","timestamp":1739853662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724007956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":453,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0031699724007956"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.121.000506","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.121.000506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}